Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 6
Submit an article Journal homepage
579
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

Alison R. WalkerDivision of Hematology, Department of Internal MedicineCorrespondence[email protected]
,
Rebecca B. KlisovicDivision of Hematology, Department of Internal Medicine
,
Ramiro GarzonDivision of Hematology, Department of Internal Medicine
,
Larry J. SchaafClinical Trials Office, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
,
Kristina HumphriesClinical Trials Office, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
,
Steven M. DevineDivision of Hematology, Department of Internal Medicine
,
John C. ByrdDivision of Hematology, Department of Internal Medicine
,
Michael R. GreverDivision of Hematology, Department of Internal Medicine
,
Guido MarcucciDivision of Hematology, Department of Internal Medicine;Department of Molecular, Cellular, and Developmental Biology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
&
William BlumDivision of Hematology, Department of Internal Medicine
 show all
Pages 1304-1308 | Received 27 Jun 2013, Accepted 06 Aug 2013, Published online: 09 Sep 2013

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Pan Xu, Guang Hu, Cheng Luo & Zhongjie Liang. (2016) DNA methyltransferase inhibitors: an updated patent review (2012-2015). Expert Opinion on Therapeutic Patents 26:9, pages 1017-1030.
Read now

Articles from other publishers (18)

Noa Biran,Pooja Phull,andand & Andre Goy. 2023. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies 331 360 .
Xin Zhao, Huan-qiu Liu, Li-na Wang, Le Yang & Xiao-liang Liu. (2022) Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities. Seminars in Cancer Biology 83, pages 121-135.
Crossref
Tuğba Erkmen, Belgin Sert Serdar, Halil Ateş, Mehmet Korkmaz & Semra Koçtürk. (2021) Borax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax/Bcl-2 Ratio in HL-60 Cell Line. Biological Trace Element Research 200:4, pages 1608-1616.
Crossref
Petra Muus, Saskia Langemeijer, Sandra van Bijnen, Nicole Blijlevens & Theo de Witte. (2021) A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia. Leukemia Research 105, pages 106573.
Crossref
Pawel Robak & Tadeusz Robak. (2019) Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs in R&D 19:2, pages 73-92.
Crossref
John Henderson, Joerg Distler & Steven O’Reilly. (2019) The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target. Trends in Molecular Medicine 25:5, pages 395-411.
Crossref
Björn Tampe & Michael Zeisberg. (2018) Chromatin dynamics at the core of kidney fibrosis. Matrix Biology 68-69, pages 194-229.
Crossref
Jacqueline Cloos, Margot SF Roeten, Niels E Franke, Johan van Meerloo, Sonja Zweegman, Gertjan JL Kaspers & Gerrit Jansen. (2017) (Immuno)proteasomes as therapeutic target in acute leukemia. Cancer and Metastasis Reviews 36:4, pages 599-615.
Crossref
May Daher, Juliana Elisa Hidalgo Lopez, Jasleen K. Randhawa, Kausar Jabeen Jabbar, Yue Wei, Naveen Pemmaraju, Gautam Borthakur, Tapan Kadia, Marina Konopleva, Hagop M. Kantarjian, Katherine Hearn, Zeev Estrov, Steven Reyes, Carlos E. Bueso-Ramos & Guillermo Garcia-Manero. (2017) An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. American Journal of Hematology 92:7, pages 674-682.
Crossref
Xin Du, Jia Tong, Hongying Lu, Cong He, Shenghong Du, Peimin Jia, Weili Zhao, Hanzhang Xu, Junmin Li, Zhixiang Shen, Yingli Wu, Jianhua Tong & Li Zhou. (2017) Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia. Molecular Medicine Reports.
Crossref
C M Csizmar, D-H Kim & Z Sachs. (2016) The role of the proteasome in AML. Blood Cancer Journal 6:12, pages e503-e503.
Crossref
T. A. L. Brevini, G. Pennarossa, E. F. M. Manzoni, C. E. Gandolfi, A. Zenobi & F. Gandolfi. (2016) The quest for an effective and safe personalized cell therapy using epigenetic tools. Clinical Epigenetics 8:1.
Crossref
Nathan Gossai, Rachel Cafferty & Brenda Weigel. (2016) Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma. Current Treatment Options in Oncology 17:7.
Crossref
Figen Atalay & Elif Birtaş Ateşoğlu. (2015) Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). Indian Journal of Hematology and Blood Transfusion 32:1, pages 46-53.
Crossref
Maximilian Stahl, Tae Kon Kim & Amer M Zeidan. (2016) Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal of Stem Cells 8:10, pages 316.
Crossref
P. Raha. 2016. Medical Epigenetics. Medical Epigenetics 799 826 .
Jianbiao Zhou, Ying Qing Ching & Wee-Joo Chng. (2015) Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target. Oncotarget 6:8, pages 5490-5500.
Crossref
Robert J. Orlowski, James K. Mangan & Selina M. Luger. (2015) Approach to patients with primary refractory acute myeloid leukemia. Current Opinion in Hematology 22:2, pages 97-107.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.